Epistasis in sporadic Alzheimer's disease

Neurobiology of Aging

Volumn 30, Issue 9, 2009, Pages 1333-1349

  Combarros, Onofre ^a   Cortina Borja, Mario ^b   Smith, A David ^c   Lehmann, Donald J ^c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antagonism; Genetic network; Heterogeneity; Metabolism; Polymorphism

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA CATENIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLINESTERASE; DOPAMINE BETA MONOOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; VASCULOTROPIN;

ALZHEIMER DISEASE; CHOLESTEROL METABOLISM; EPISTASIS; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INFLAMMATION; MARKER GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEIN E4; ASPARTIC ENDOPEPTIDASES; CHOLESTEROL; ENCEPHALITIS; EPISTASIS, GENETIC; HUMANS; INTERLEUKIN-6; OXIDATIVE STRESS;

EID: 67650470272     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.11.027     Document Type: Review

References (184)

1. Abraham R., Myers A., Wavrant-DeVrieze F., Hamshere M.L., Thomas H.V., Marshall H., Compton D., Spurlock G., Turic D., Hoogendoorn B., Kwon J.M., Petersen R.C., Tangalos E., Norton J., Morris J.C., Bullock R., Liolitsa D., Lovestone S., Hardy J., Goate A., O'Donovan M., Williams J., Owen M.J., and Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum. Genet. 109 (2001) 646-652
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Hull M., Landreth G., Lue L.-F., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
3. American Psychiatric Association. DSM-III-R. Diagnostic and Statistical manual of mental disorders. 3rd rev ed. (1987), American Psychiatric Association, Washington, DC
4. American Psychiatric Association. DSM-IV. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington
5. Arias-Vásquez A., Isaacs A., Aulchenko Y.S., Hofman A., Oostra B.A., Breteler M., and Van Duijn C.M. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8 (2007) 189-193
6. 2-macroglobulin influences the risk for Alzheimer's Disease. Ann. Neurol. 47 (2000) 138-139
7. Bagnoli S., Cellini E., Tedde A., Nacmias B., Piacentini S., Bessi V., Bracco L., and Sorbi S. Association of IL10 promoter polymorphism in Italian Alzheimer's disease. Neurosci. Lett. 418 (2007) 262-265
8. Bernardini S., Bellincampi L., Ballerini S., Federici G., Iori R., Trequattrini A., Ciappi F., Baldinetti F., Bossù P., Caltagirone C., and Spalletta G. Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E ε4 allele. Clin. Chem. 51 (2005) 944-951
9. Berrington de González A., and Cox D.R. Additive and multiplicative models for the joint effect of two risk factors. Biostatistics 6 (2005) 1-9
10. Bhojak T.J., DeKosky S.T., Ganguli M., and Kamboh M.I. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci. Lett. 288 (2000) 21-24
11. Bian L., Yang J.D., Guo T.W., Sun Y., Duan S.W., Chen W.Y., Pan Y.X., Feng G.Y., and He L. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology 63 (2004) 241-245
12. Bian J.-T., Zhang J.-W., Zhang Z.-X., and Shao H.-L. Association analysis of brain-derived neurotrophic factor (BDNF) gene 196A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese. Neurosci. Lett. 387 (2005) 11-16
13. Blázquez L., De Juan D., Ruiz-Martínez J., Emparanza J.I., Sáenz A., Otaegui D., Sistiaga A., Martínez-Lage P., Lamet I., Samaranch L., Buiza C., Etxeberria I., Arriola E., Cuadrado E., Urdaneta E., Yanguas J., and López de Munain A. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiol. Aging. 28 (2007) 1941-1943
14. Bosco P., Caraci F., Copani A., Spada R.S., Sortino M.A., Salluzzo R., Salemi M., Nicoletti F., and Ferri R. The CDC2 I-G-T haplotype associated with the APOE ε4 allele increases the risk of sporadic Alzheimer's disease in Sicily. Neurosci. Lett. 419 (2007) 195-198
15. Brune S., Kölsch H., Ptok U., Majores M., Schulz A., Schlosser R., Rao M.L., Maier W., and Heun R. Polymorphism in the peroxisome proliferator-activated receptor α gene influences the risk for Alzheimer's disease. J. Neural. Transm. 110 (2003) 1041-1050
16. Bullido M.J., Guallar-Castillón P., Artiga M.J., Ramos M.C., Sastre I., Aldudo J., Frank A., Coria F., Rodríguez-Artalejo F., and Valdivieso F. Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neurosci. Lett. 289 (2000) 213-216
17. Bullido M.J., Ramos M.C., Ruiz-Gómez A., Tutor A.S., Sastre I., Frank A., Coria F., Gil P., Mayor F.J., and Valdivieso F. Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiol. Aging 25 (2004) 853-859
18. Cai L., Tang G., Chen L., Zhang B., Jiang S., and Ren D. Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients. Neuroreport 16 (2005) 1023-1026
19. Capurso C., Solfrizzi V., D'Introno A., Colacicco A.M., Capurso S.A., Capurso A., and Panza F. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp. Gerontol. 39 (2004) 1567-1573
20. Carter C.J. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem. Int. 50 (2007) 12-38
21. Cash A.D., Perry G., Ogawa O., Raina A.K., Zhu X., and Smith M.A. Is Alzheimer's disease a mitochondrial disorder?. Neuroscientist 8 (2002) 489-496
22. Cathcart H.M., Hsuang R., Lanham I.S., Corder E.H., and Poduslo S.E. Cystatin C as a risk factor for Alzheimer disease. Neurology 64 (2005) 755-757
23. Cellini E., Bagnoli S., Tedde A., Nacmias B., Piacentini S., and Sorbi S. Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19 (2005) 246-247
24. Chapuis J., Tian J., Shi J., Bensemain F., Cottel D., Lendon C., Amouyel P., Mann D., and Lambert J.-C. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol. Aging 27 (2006) 1212-1215
25. Chen D., Zhang J.-W., Zhang Z.-X., Wu Y.-N., and Qu Q.-M. Association of α2-macroglobulin polymorphisms and Alzheimer disease in mainland Han Chinese. J. Neurol. Sci. 217 (2004) 13-15
26. Cheng D., Huang R., Lanham I.S., Cathcart H.M., Howard M.E.H., and Poduslo C.S.E. Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J. Med. Genet. 42 (2005) 129-131
27. Chiappelli M., Borroni B., Archetti S., Calabrese E., Corsi M.M., Franceschi M., Padovani A., and Licastro F. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res. 9 (2006) 485-493
28. Cho Y.M., Ritchie M.D., Moore J.H., Park J.Y., Lee K.-U., Shin H.D., Lee H.K., and Park K.S. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 47 (2004) 549-554
29. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71 (Suppl.) (2000) 621S-629S
30. Clarimon J., Bertranpetit J., Calafell F., Boada M., Tarraga L., and Comas D. Association study between Alzheimer's disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol. 250 (2003) 956-961
31. Combarros O., Infante J., Llorca J., Peña N., Fernández-Viadero C., and Berciano J. The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis. Neurosci. Lett. 326 (2002) 33-36
32. Combarros O., García-Román M., Fontalba A., Fernández-Luna J.L., Llorca J., Infante J., and Berciano J. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement Geriatr. Cogn. Disord. 15 (2003) 151-154
33. Combarros O., Infante J., Llorca J., and Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 18 (2004) 257-260
34. Combarros O., Infante J., Llorca J., Peña N., Fernández-Viadero C., and Berciano J. Interaction between interleukin-6 and intercellular adhesion molecule-1 genes and Alzheimer's disease risk. J. Neurol. 252 (2005) 485-487
35. Combarros O., Riancho J.A., Infante J., Sañudo C., Llorca J., Zarrabeitia M.T., and Berciano J. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 20 (2005) 153-157
36. Combarros O., Llorca J., Sánchez-Juan P., Mateo I., Infante J., Rodríguez E., Sánchez-Quintana C., and Berciano J. Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer's disease risk. J. Neurol. 254 (2007) 115-117
37. Combarros O., Riancho J.A., Arozamena J., Mateo I., Llorca J., Infante J., Sánchez-Juan P., Zarrabeitia M.T., and Berciano J. Interaction between estrogen receptor-α and butyrylcholinesterase genes modulates Alzheimer's disease risk. J. Neurol. 254 (2007) 1290-1292
38. Compton D., Wavrant DeVrièze F., Petersen R.C., Tangalos E., Li L., and Hardy J. Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers. Neurosci. Lett. 331 (2002) 60-62
39. Crawford F.C., Freeman M.J., Schinka J.A., Morris M.D., Abdullah L.I., Richards D., Sevush S., Duara R., and Mullan M.J. Association between Alzheimer's disease and a functional polymorphism in the myeloperoxidase gene. Exp. Neurol. 167 (2001) 456-459
40. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron 38 (2003) 9-12
41. Del Bo R., Scarlato M., Ghezzi S., Martinelli Boneschi F., Fenoglio C., Galbiati S., Virgilio R., Galimberti D., Galimberti G., Crimi M., Ferrarese C., Scarpini E., Bresolin N., and Comi G.P. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann. Neurol. 57 (2005) 373-380
42. Dermaut B., Theuns J., Sleegers K., Hasegawa H., Van den Broeck M., Vennekens K., Corsmit E., St George-Hyslop P., Cruts M., van Duijn C.M., and Van Broeckhoven C. The gene encoding nicastrin, a major γ-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. Am. J. Hum. Genet. 70 (2002) 1568-1574
43. Desai P., DeKosky S.T., and Kamboh M.I. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci. Lett. 328 (2002) 9-12
44. Di Natale M., Perri M., Kawarai T., Maletta R., Tomaino C., Sato C., Nacmias B., Shibata N., Sorbi S., St George-Hyslop P.H., Bruni A.C., and Rogaeva E. Absence of association between Alzheimer's disease and the regulatory region polymorphism of the PS2 gene in an Italian population. Neurosci. Lett. 343 (2003) 210-212
45. Dickson M.R., Perry R.T., Wiener H., and Go R.C.P. Association studies of transforming growth factor-β1 and Alzheimer's disease. Am. J. Med. Genet. B (Neuropsychiatr. Genet.) 139B (2005) 38-41
46. D'Introno A., Solfrizzi V., Colacicco A.M., Capurso C., Torres F., Capurso S.A., Capurso A., and Panza F. Polymorphisms in the oxidized low-density lipoprotein receptor-1 gene and risk of Alzheimer's disease. J. Gerontol. A 60 (2005) 280-284
47. Edland S.D., Wavrant-De Vrièse F., Compton D., Smith G.E., Ivnik R., Boeve B.F., Tangalos E.G., and Petersen R.C. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci. Lett. 345 (2003) 21-24
48. Eerligh P., Koeleman B.P.C., Dudbridge F., Bruining G.J.B.O., and Giphart R.M.J. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immunity 5 (2004) 36-40
49. Ezquerra M., Blesa R., Tolosa E., Ballesta F., and Oliva R. α-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population. Neurosci. Lett. 240 (1998) 107-109
50. Fallin D., Reading S., Schinka J., Hoyne J., Scibelli P., Gold M., Crawford F., and Mullan M. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am. J. Med. Genet. (Neuropsych. Genet.) 74 (1997) 192-194
51. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., and van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis; the APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997) 1349-1356
52. Farrer L.A., Abraham C.R., Haines J.L., Rogaeva E.A., Song Y., McGraw W.T., Brindle N., Premkumar S., Scott W.K., Yamaoka L.H., Saunders A.M., Roses A.D., Auerbach S.A., Sorbi S., Duara R., Pericak-Vance M.A., and St George-Hyslop P.H. Association between bleomycin hydrolase and Alzheimer's disease in Caucasians. Ann. Neurol. 44 (1998) 808-811
53. Feinstein D.L., Heneka M.T., Gavrilyuk V., Russo C.D., Weinberg G., and Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41 (2002) 357-365
54. Feuk L., Prince J.A., Breen G., Emahazion T., Carothers A., St Clair D., and Brookes A.J. Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum. Genet. 107 (2000) 391-396
55. Flex A., Gaetani E., Papaleo P., Straface G., Proia A.S., Pecorini G., Tondi P., Pola P., and Pola R. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 35 (2004) 2270-2275
56. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10 (1999) 245-257
57. Gambaro G., Anglani F., and D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet 355 (2000) 308-311
58. Golanska E., Hulas-Bigoszewska K., Wojcik I., Rieske P., Styczynska M., Peplonska B., Pfeffer A., Luczywek E., Wasiak B., Gabryelewicz T., Religa D., Chodakowska-Zebrowska M., Barcikowska M., Sobow T., and Liberski P.P. CYP46: a risk factor for Alzheimer's disease or a coincidence?. Neurosci. Lett. 383 (2005) 105-108
59. Gold G., Blouin J.L., Herrmann F.R., Michon A., Mulligan R., Duriaux Saïl G., Bouras C., Giannakopoulos P., and Antonarakis S.E. Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE ε4 carriers. Am. J. Med. Genet. B 119 (2003) 44-47
60. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., and Heinecke J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem. 90 (2004) 724-733
61. Grubber J.M., Saunders A.M., Crane-Gatherum A.R., Scott W.K., Martin E.R., Haynes C.S., Conneally P.M., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci. Lett. 269 (1999) 115-119
62. Guerre-Millo M., Gervois P., Raspé E., Madsen L., Poulain P., Derudas B., Herbert J.M., Winegar D.A., Willson T.M., Fruchart J.C., Berge R.K., and Staels B. Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275 (2000) 16638-16642
63. 1-antichymotrypsin in Alzheimer disease. Genomics 33 (1996) 53-56
64. Harold D., Jehu L., Turic D., Hollingworth P., Moore P., Summerhayes P., Moskvina V., Foy C., Archer N., Hamilton B.A., Lovestone S., Powell J., Brayne C., Rubinsztein D.C., Jones L., O'Donovan M.C., Owen M.J., and Williams J. Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. Am. J. Med. Genet. Part B 144 (2007) 448-452
65. Hatanaka Y., Kamino K., Fukuo K., Mitsuda N., Nishiwaki-Ueda Y., Sato N., Satoh T., Yamamoto H., Yoneda H., Imagawa M., Miki T., Ohta S., and Ogihara T. Low density lipoprotein receptor-related protein gene polymorphisms and risk for late-onset Alzheimer's disease in a Japanese population. Clin. Genet. 58 (2000) 319-323
66. Healy D.G. Case-control studies in the genomic era: a clinician's guide. Lancet Neurol. 5 (2006) 701-707
67. Helbecque N., Cottel D., Hermant X., and Amouyel P. Impact of the matrix metalloproteinase MMP-3 on dementia. Neurobiol. Aging 28 (2007) 1215-1220
68. Hernandez-Charro B., Moreno S., Valiente A., Manubens J.M., Villar M.D., and Ramos-Arroyo M.A. ACT/AA polymorphism could duplicate the APOE*ε4-associated Alzheimer's disease risk. Med. Clin. (Barc.) 123 (2004) 251-254
69. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29 (2001) 571-581
70. Howlett D.R., Simmons D.L., Dingwall C., and Christie G. In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase. Trends Neurosci. 23 (2000) 565-570
71. Huang R., Huang J., Cathcart H., Smith S., and Poduslo S.E. Genetic variants in brain-derived neurotrophic factor associated with Alzheimer's disease. J. Med. Genet. 44 (2007) e66
72. Hyman B.T., Strickland D., and Rebeck G.W. Role of the low-density lipoprotein receptor-related protein in β-amyloid metabolism and Alzheimer's disease. Arch. Neurol. 57 (2000) 646-650
73. Iivonen S., Helisalmi S., Mannermaa A., Alafuzoff I., Lehtovirta M., Soininen H., and Hiltunen M. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology. Neurosci. Lett. 352 (2003) 146-150
74. Infante J., Sanz C., Fernández-Luna J.L., Llorca J., Berciano J., and Combarros O. Gene-gene interaction between interleukin-1A and interleukin-8 increases Alzheimer's disease risk. J. Neurol. 251 (2004) 482-483
75. Infante J., Sanz C., Fernández-Luna J.L., Llorca J., Berciano J., and Combarros O. Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology 63 (2004) 1135-1136
76. Infante J., Llorca J., Mateo I., Rodríguez-Rodríguez E., Sánchez-Quintana C., Sánchez-Juan P., Fernández-Viadero C., Peña N., Berciano J., and Combarros O. Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement. Geriatr. Cogn. Disord. 23 (2007) 215-218
77. In't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
78. Ioannidis J.P.A., Ntzani E.E., Trikalinos T.A., and Contopoulos-Ioannidis D.G. Replication validity of genetic association studies. Nat. Genet. 29 (2001) 306-309
79. Ioannidis J.P.A., Trikalinos T.A., Nitzani E.E., and Contopoulos-Ioannidis D.G. Genetic associations in large versus small studies: an empirical assessment. Lancet 361 (2003) 567-571
80. Janciauskiene S., Rubin H., Lukacs C.M., and Wright H.T. Alzheimer's peptide Aβ1-42 binds to two β-sheets of α1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 273 (1998) 28360-28364
81. Jia L., Ye J., Haiyan L.V., Wang W., Zhou C., Zhang X., Xu J., Wang L., and Jia J. Genetic association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the North Chinese population. Brain Res. 1141 (2007) 10-14
82. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
83. Johansson A., Katzov H., Zetterberg H., Feuk L., Johansson B., Bogdanovic N., Andreasen N., Lenhard B., Brookes A.J., Pedersen N.L., Blennow K., and Prince J.A. Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum. Genet. 114 (2004) 581-587
84. Kajiya A., Kaji H., Isobe T., and Takeda A. Precessing of amyloid β-peptides by neutral cysteine protease bleomycin hydrolase. Protein Pept. Lett. 13 (2006) 119-123
85. Kamboh M.I., Sanghera D.K., Ferrell R.E., and DeKosky S.T. APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nat. Genet. 10 (1995) 486-488
86. Kamino K., Nagasaka K., Imagawa M., Yamamoto H., Yoneda H., Ueki A., Kitamura S., Namekata K., Miki T., and Ohta S. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem. Biophys. Res. Commun. 273 (2000) 192-196
87. Keller J.N., Hanni K.B., and Markesbery W.R. Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J. Neurochem. 72 (1999) 2601-2609
88. Kim J.-M., Stewart R., Shin I.-S., Jung J.-S., and Yoon J.-S. Assessment of association between mitochondrial aldehyde dehydrogenase polymorphism and Alzheimer's disease in an older Korean population. Neurobiol. Aging 25 (2004) 295-301
89. Kim K.-W., Suh Y.-J., Park W.-Y., Jhoo J.-H., Lee D.-Y., Youn J.-C., Lee K.-H., Seo J.-S., and Woo J.-I. Choline acetyltransferase G + 4 A polymorphism confers a risk for Alzheimer's disease in concert with apolipoprotein E ε4. Neurosci. Lett. 366 (2004) 182-186
90. Kirschling C.M., Kölsch H., Frahnert C., Rao M.L., Maier W., and Heun R. Polymorphism in the BACE gene influences the risk for Alzheimer's disease. Neuroreport 14 (2003) 1243-1246
91. Kita T., Kume N., Minami M., Hayashida K., Murayama T., Sano H., Moriwaki H., Kataoka H., Nishi E., Horiuchi H., Arai H., and Yokode M. Role of oxidized LDL in atherosclerosis. Ann. N.Y. Acad. Sci. 947 (2001) 199-205
92. Koivisto A.M., Helisalmi S., Pihlajamäki J., Moilanen L., Kuusisto J., Laakso M., Hiltunen M., Keijo K., Hänninen T., Helkala E.-L., Kervinen K., Kesäniemi Y.A., and Soininen H. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J. Neurogenet. 19 (2005) 155-161
93. Koster M.N., Dermaut B., Cruts M., Houwing-Duistermaat J.J., Roks G., Tol J., Ott A., Hofman A., Munteanu G., Breteler M.M.B., van Duijn C.M., and Van Broeckhoven C. The α2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 55 (2000) 678-684
94. Kuwano R., Miyashita A., Arai H., Asada T., Imagawa M., Shoji M., Higuchi S., Urakami K., Kakita A., Takahashi H., Tsukie T., Toyabe S., Akazawa K., Kanazawa I., and Ihara Y. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease: the Japanese Genetic Study Consortium for Alzheimer's Disease. Hum. Mol. Genet. 15 (2006) 2170-2182
95. Lambert J.C., Luedecking-Zimmer E., Merrot S., Hayes A., Thaker U., Desai P., Houzet A., Hermant X., Cottel D., Pritchard A., Iwatsubo T., Pasquier F., Frigard B., Conneally P.M., Chartier-Harlin M.C., DeKosky S.T., Lendon C., Mann D., Kamboh M.I., and Amouyel P. Association of 3′-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. J. Med. Genet. 40 (2003) 424-430
96. Lambert J.-C., Mann D., Harris J., Araria-Goumidi L., Chartier-Harlin M.-C., Cottel D., Iwatsubo T., Amouyel P., and Lendon C. Association study of notch 4 polymorphisms with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 377-381
97. Lehmann D.J., Johnston C., and Smith A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 6 (1997) 1933-1936
98. Lehmann D.J., Williams J., McBroom J., and Smith A.D. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 108 (2001) 541-554
99. Leininger-Muller B., Hoy A., Herbeth B., Pfister M., Serot J.-M., Stavljenic-Rukavina M., Massana L., Passmore P., Siest G., and Visvikis S. Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neurosci. Lett. 349 (2003) 95-98
100. Li X.-Q., Chen D., Zhang Z.-X., Qu Q.-M., and Zhang J.-W. Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population. Dement. Geriatr. Cogn. Disord. 18 (2004) 115-119
101. Licastro F., Chiappelli M., Grimaldi L.M.E., Morgan K., Kalsheker N., Calabrese E., Ritchie A., Porcellini E., Salani G., Franceschi M., and Canal N. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol. Aging 26 (2005) 449-453
102. Lim U., Peng K., Shane B., Stover P.J., Litonjua A.A., Weiss S.T., Gaziano J.M., Strawderman R.L., Raiszadeh F., Selhub J., Tucker K.L., and Cassano P.A. Polymorphisms in cytoplasmic serine hydroxymethyltransferase and methylenetetrahydrofolate reductase affect the risk of cardiovascular disease in men. J. Nutr. 135 (2005) 1989-1994
103. Luedecking-Zimmer E., DeKosky S.T., Chen Q., Barmada M.M., and Kamboh M.I. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum. Genet. 111 (2002) 443-451
104. Ma D.Q., Whitehead P.L., Menold M.M., Martin E.R., Ashley-Koch A.E., Mei H., Ritchie M.D., DeLong G.R., Abramson R.K., Wright H.H., Cuccaro M.L., Hussman J.P., Gilbert J.R., and Pericak-Vance M.A. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am. J. Hum. Genet. 77 (2005) 377-388
105. Mariani E., Seripa D., Ingegni T., Nocentini G., Mangialasche F., Ercolani S., Cherubini A., Metastasio A., Pilotto A., Senin U., and Mecocci P. Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. J. Neurol. Sci. 247 (2006) 187-191
106. Martin M.P., Gao X., Lee J.-H., Nelson G.W., Detels R., Goedert J.J., Buchbinder S., Hoots K., Vlahov D., Trowsdale J., Wilson M., O'Brien S.J., and Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31 (2002) 429-434
107. Martin E.R., Bronson P.G., Li Y.-J., Wall N., Chung R.-H., Schmechel D.E., Small G., Xu P.-T., Bartlett J., Schnetz-Boutaud N., Haines J.L., Gilbert J.R., and Pericak-Vance M.A. Interaction between the α-T catenin gene (VR22) and APOE in Alzheimer's disease. J. Med. Genet. 42 (2005) 787-792
108. Mateo I., Infante J., Rodríguez E., Berciano J., and Combarros O. Interaction between dopamine β-hydroxylase and interleukin genes increases Alzheimer's disease risk. J. Neurol. Neurosurg. Psychiatry 77 (2006) 278-279
109. Matsubara-Tsutsui M., Yamagata H., Morishima A., Nakura J., Mitsuda N., Kamino K., Kondo I., and Miki T. The -4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. Intern. Med. 41 (2002) 823-828
110. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
111. McCusker S.M., Curran M.D., Dynan K.B., McCullagh C.D., Urquhart D.D., Middleton D., Patterson C.C., McIlroy S.P., and Passmore A.P. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357 (2001) 436-439
112. McIlroy S.P., Vahidassr M.D., Savage D.A., Lloyd F., Patterson C.C., Lawson J.T., and Passmore A.P. Association of serum AACT levels and AACT signal polymorphism with late-onset Alzheimer's disease in Northern Ireland. Int. J. Geriat. Psychiatry 15 (2000) 260-266
113. McIlroy S.P., Dynan K.B., Vahidassr D.J., Lawson J.T., Patterson C.C., and Passmore P. Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. Am. J. Med. Genet. (Neuropsych. Genet.) 105 (2001) 502-506
114. McIntire W.E., MacCleery G., and Garrison J.C. The G protein β subunit is a determinant in the coupling of Gs to the β1-adrenergic and A2a adenosine receptors. J. Biol. Chem. 276 (2001) 15801-15809
115. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
116. Mesulam M.-M., and Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36 (1994) 722-727
117. Minster R.L., DeKosky S.T., and Kamboh M.I. No association of dynamin binding protein (DNMBP) gene SNPs and Alzheimer's disease. Neurobiol. Aging (2007) (Epub ahead of print)
118. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., and Berg L. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
119. Montoya S.E., Aston C.E., DeKosky S.T., Kamboh M.I., Lazo J.S., and Ferrell R.E. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat. Genet. 18 (1998) 211-212
120. Moore J.H., and Williams S.M. New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34 (2002) 88-95
121. Moore J.H., and Williams S.M. Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. BioEssays 27 (2005) 637-646
122. 1-antichymotrypsin gene locus associated with sporadic Alzheimer's disease. Hum. Genet. 99 (1997) 27-31
123. Morikawa M., Fryer J.D., Sullivan P.M., Christopher E.A., Wahrle S.E., DeMattos R.B., O'Dell M.A., Fagan A.M., Lashuel H.A., Walz T., Asai K., and Holtzman D.M. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β. Neurobiol. Dis. 19 (2005) 66-76
124. Muramatsu T., Matsushita S., Arai H., Sasaki H., and Higuchi S. α1-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease. J. Neural. Transm. 103 (1996) 1205-1210
125. Musani S.K., Shriner D., Liu N., Feng R., Coffey C.S., Yi N., Tiwari H.K., and Allison D.B. Detection of gene x gene interactions in genome-wide association studies of human population data. Hum. Hered. 63 (2007) 67-84
126. Nagy Z., Esiri M.M., Hindley N.J., Joachim C., Morris J.H., King E.M.-F., McDonald B., Litchfield S., Barnetson L., Jobst K.A., and Smith A.D. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement. Geriatr. Cogn. Disord. 9 (1998) 219-226
127. Nicoll J.A.R., Mrak R.E., Graham D.I., Stewart J., Wilcock G., MacGowan S., Esiri M.M., Murray L.S., Dewar D., Love S., Moss T., and Griffin W.S.T. Association of Interleukin-1 gene polymorphisms with Alzheimer's disease 47 (2000) 365-368
128. Nowotny P., Kwon J.M., Chakraverty S., Nowotny V., Morris J.C., and Goate A.M. Association studies using novel polymorphisms in BACE1 and BACE2. Neuroreport 12 (2001) 1799-1802
129. Ntais C., Polycarpou A., and Ioannidis J.P.A. Meta-analysis of the association of the cathepsin D Ala224Val gene polymorphism with the risk of Alzheimer's disease: a HuGE gene-disease association review. Am. J. Epidemiol. 159 (2004) 527-536
130. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., and Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
131. Ott J. Association of genetic loci: replication or not, that is the question. Neurology 63 (2004) 955-958
132. Panza F., Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Capurso A., and Kehoe P.G. Shifts in angiotensin 1 converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1159-1161
133. Papassotiropoulos A., Bagli M., Jessen F., Frahnert C., Rao M.L., Maier W., and Heun R. Confirmation of the association between bleomycin hydrolase genotype and Alzheimer's disease. Mol. Psychiatry 5 (2000) 213-215
134. Perry G., Nunomura A., Hirai K., Zhu X., Pérez M., Avila J., Castellani R.J., Atwood C.S., Aliev G., Sayre L.M., Takeda A., and Smith M.A. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Rad. Biol. Med. 33 (2002) 1475-1479
135. Pesaresi M., Batelli S., Prato F., Polito L., Lovati C., Scarpini E., Quadri P., Mariani C., Albani D., and Forloni G. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-ε4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Aβ(1-42) level. Neurobiol. Dis. 25 (2007) 609-613
136. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 9 (2003) 94-101
137. Poli M., Gatta L.B., Archetti S., Padovani A., Albertini A., and Finazzi D. Association analysis between anterior-pharynx defective-1 genes polymorphisms and Alzheimer's disease. Neurosci. Lett. 350 (2003) 77-80
138. Poli M., Gatta L.B., Lovati C., Mariani C., Galimberti D., Scarpini E., Biunno I., Musicco M., Dominici R., Albertini A., and Finazzi D. Interaction between the APOE ε4 allele and the APH-1b c + 651T > G SNP in Alzheimer's disease. Neurobiol. Aging (2007) (Epub ahead of print)
139. Porrello E., Monti M.C., Sinforiani E., Cairati M., Guaita A., Montomoli C., Govoni S., and Racchi M. Estrogen receptor α and APOEε4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur. J. Neurol. 13 (2006) 639-644
140. Praticò D., and Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimer's Dis. 6 (2004) 171-175
141. Qin S., Zhao X., Pan Y., Liu J., Feng G., Fu J., Bao J., Zhang Z., and He L. An association study of the N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur. J. Hum. Genet. 13 (2005) 807-814
142. Quan W., Yasuda M., Hashimoto M., Yamamoto Y., Ishii K., Kazui H., Mori E., Kakigi T., and Maeda K. Polymorphism of the regulatory region of the presenilin-2 gene in sporadic Alzheimer's disease: a case-control study. J. Neurol. Sci. 240 (2006) 71-75
143. Raina A.K., Takeda A., Nunomura A., Perry G., and Smith M.A. Genetic evidence for oxidative stress in Alzheimer's disease. NeuroReport 10 (1999) 1355-1357
144. Raygani A.V., Zahrai M., Soltanzadeh A., Doosti M., Javadi E., and Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci. Lett. 371 (2004) 142-146
145. Relton C.L., Wilding C.S., Pearce M.S., Laffling A.J., Jonas P.A., Lynch S.A., Tawn E.J., and Burn J. Gene-gene interaction in folate-related genes and risk of neural tube defects in a UK population. J. Med. Genet. 41 (2004) 256-260
146. Remarque E.J., Bollen E.L., Weverling-Rijnsburger A.W., Laterveer J.C., Blauw G.J., and Westendorp R.G. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp. Gerontol. 36 (2001) 171-176
147. Reynolds W.F., Hiltunen M., Pirskanen M., Mannermaa A., Helisalmi S., Lehtovirta M., Alafuzoff I., and Soininen H. MPO and APOEε4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 55 (2000) 1284-1290
148. Riazanskaia N., Lukiw W.J., Grigorenko A., Korovaitseva G., Dvoryanchikov G., Moliaka Y., Nicolaou M., Farrer L., Bazan N.G., and Rogaev E.I. Regulatory region variability in the human presenilin-2 (PSEN2) gene: potential contribution to the gene activity and risk for AD. Mol. Psychiatry 7 (2002) 891-898
149. Ritchie M.D., Hahn L.W., Roodi N., Bailey L.R., Dupont W.D., Parl F.F., and Moore J.H. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am. J. Hum. Genet. 69 (2001) 138-147
150. Robson K.J.H., Lehmann D.J., Wimhurst V.L.C., Livesey K.J., Combrinck M., Merryweather-Clarke A.T., Warden D.R., and Smith A.D. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J. Med. Genet. 41 (2004) 261-265
151. Rodríguez E., Mateo I., Infante J., Llorca J., Berciano J., and Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE ε4 allele. J. Neurol. 253 (2006) 181-185
152. Rodríguez E., Mateo I., Llorca J., Sánchez-Quintana C., Infante J., Berciano J., and Combarros O. Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk. J. Neurol. 253 (2006) 801-803
153. Rodríguez-Rodríguez E., Mateo I., Llorca J., Sánchez-Quintana C., Infante J., García-Gorostiaga I., Sánchez-Juan P., Berciano J., and Combarros O. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am. J. Med. Genet. Part B 144 (2007) 964-968
154. Rogers J., Strohmeyer R., Kovelowski C.J., and Li R. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. GLIA 40 (2002) 260-269
155. Sakai A., Ujike H., Nakata K., Takehisa Y., Imamura T., Uchida N., Kanzaki A., Yamamoto M., Fujisawa Y., Okumura K., and Kuroda S. No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population. Am. J. Med. Genet. Part B 125 (2004) 87-91
156. Sala Frigerio C., Piscopo P., Calabrese E., Crestini A., Malvezzi Campeggi L., Civita di Fava R., Fogliarino S., Albani D., Marcon G., Cherchi R., Piras R., Forloni G., and Confaloni A. PEN-2 gene mutation in a familial Alzheimer's disease case. J. Neurol. 252 (2005) 1033-1036
157. Sheu K.-F.R., Brown A.M., Haroutunian V., Kristal B.S., Thaler H., Lesser M., Kalaria R.N., Relkin N.R., Mohs R.C., Lilius L., Lannfelt L., and Blass J.P. Modulation by DLST of the genetic risk of Alzheimer's disease in a very elderly population. Ann. Neurol. 45 (1999) 48-53
158. Sheu K.-F.R., Brown A.M., Kristal B.S., Kalaria R.N., Lilius L., Lannfelt L., and Blass J.P. A DLST genotype associated with reduced risk for Alzheimer's disease. Neurology 52 (1999) 1505-1507
159. Shibata N., Kawarai T., Lee J.H., Lee H.-S., Shibata E., Sato C., Liang Y., Duara R., Mayeux R.P., St George-Hyslop P.H., and Rogaeva E. Association studies of cholesterol metabolism genes (CH25H ABCA1 and CH24H) in Alzheimer's disease. Neurosci. Lett. 391 (2006) 142-146
160. Shobab L.A., Hsiung G-YR, and Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 4 (2005) 841-852
161. Singleton A.B., Smith G., Gibson A.M., Woodward R., Perry R.H., Ince P.G., Edwardson J.A., and Morris C.M. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum. Mol. Genet. 7 (1998) 937-939
162. Spell C., Kölsch H., Lütjohann D., Kerksiek A., Hentschel F., Damian M., von Bergmann K., Rao M.L., Maier W., and Heun R. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele. Dement. Geriatr. Cogn. Disord. 18 (2004) 245-249
163. Stephens J.W., and Humphries S.E. The molecular genetics of cardiovascular disease: clinical implications. J. Intern. Med. 253 (2003) 120-127
164. Streit W.J., Conde J.R., and Harrison J.K. Chemokines and Alzheimer's disease. Neurobiol. Aging 22 (2001) 909-913
165. Talbot C., Houlden H., Craddock N., Crook R., Hutton M., Lendon C., Prihar G., Morris J.C., Hardy J., and Goate A. Polymorphism in AACT gene may lower age of onset of Alzheimer's disease. Neuroreport 7 (1996) 534-536
166. Tanzi R.E., Moir R.D., and Wagner S.L. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 43 (2004) 605-608
167. Terreni L., Fogliarino S., Quadri P., Ruggieri R.M.F.P., Tettamanti M., Lucca U., and Forloni G. Tumor necrosis factor α polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population. Neurosci. Lett. 344 (2003) 135-137
168. Thornton-Wells T.A., Moore J.H., and Haines J.L. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet. 20 (2004) 640-647
169. Tilley L., Morgan K., Grainger J., Marsters P., Morgan L., Lowe J., Xuereb J., Wischik C., Harrington C., and Kalsheker N. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur. J. Hum. Genet. 7 (1999) 659-663
170. Tsai C.-T., Lai L.-P., Lin J.-L., Chiang F.-T., Hwang J.-J., Ritchie M.D., Moore J.H., Hsu K.-L., Tseng C.-D., Liau C.-S., and Tseng Y.-Z. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 109 (2004) 1640-1646
171. Uchida N., Ujike H., Tanaka Y., Sakai A., Yamamoto M., Fujisawa Y., Kanzaki A., and Kuroda S. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am. J. Geriatr. Psychiatry 13 (2005) 1062-1066
172. van Oijen M., Arp P.P., de Jong F.J., Hofman A., Koudstaal P.J., Uitterlinden A.G., and Breteler M.M.B. Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia: the Rotterdam Study. Neurosci. Lett. 402 (2006) 113-117
173. Wade M.J. Epistasis, complex traits, and mapping genes. Genetica 112/113 (2001) 59-69
174. Wang B., Zhang C., Zheng W., Lu Z., Zheng C., Yang Z., Wang L., and Jin F. Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. Neurosci. Lett. 369 (2004) 104-107
175. Wiebusch H., Poirier J., Sévigny P., and Schappert K. Further evidence for a synergistic association between APOEε4 and BCHE-K in confirmed Alzheimer's disease. Hum. Genet. 104 (1999) 158-163
176. Williams S.M., Addy J.H., Phillips JAr, Dai M., Kpodonu J., Afful J., Jackson H., Joseph K., Eason F., Murray M.M., Epperson P., Aduonum A., Wong L.-J., Jose P.A., and Felder R.A. Combinations of variations in multiple genes are associated with hypertension. Hypertension 36 (2000) 2-6
177. Williams S.M., Ritchie M.D., Phillips J.Ar., Dawson E., Prince M., Dzhura E., Willis A., Semenya A., Summar M., White B.C., Addy J.H., Kpodonu J., Wong L.-J., Felder R.A., Jose P.A., and Moore J.H. Multilocus analysis of hypertension: a hierarchical approach. Hum. Hered. 57 (2004) 28-38
178. Wollmer M.A., Sleegers K., Ingelsson M., Zekanowski C., Brouwers N., Maruszak A., Brunner F., Huynh K.D., Kilander L., Brundin R.M., Hedlund M., Giedraitis V., Glaser A., Engelborghs S., De Deyn P.P., Kapaki E., Tsolaki M., Daniilidou M., Molyva D., Paraskevas G.P., Thal D.R., Barcikowska M., Kuznicki J., Lannfelt L., Van Broeckhoven C., Nitsch R.M., Hock C., and Papassotiropoulos A. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 8 (2007) 179-188
179. Xiong M., Feghali-Bostwick C.A., Arnett F.C., and Zhou X. A systems biology approach to genetic studies of complex diseases. FEBS Lett. 579 (2005) 5325-5332
180. Yamada R., Tanaka T., Unoki M., Nagai T., Sawada T., Ohnishi Y., Tsunoda T., Yukioka M., Maeda A., Suzuki K., Tateishi H., Ochi T., Nakamura Y., and Yamamoto K. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am. J. Hum. Genet. 68 (2001) 674-685
181. Ye S., Dhillon S., Seear R., Dunleavey L., Day L.B., Bannister W., Day I.N.M., and Simpson I. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart 89 (2003) 1195-1199
182. Yoshiiwa A., Kamino K., Yamamoto H., Kobayashi T., Imagawa M., Nonomura Y., Yoneda H., Sakai T., Nishiwaki Y., Sato N., Rakugi H., Miki T., and Ogihara T. α1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E ε4 allele carriers. Ann. Neurol. 42 (1997) 115-117
183. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62 (2005) 217-224
184. Zappia M., Manna I., Serra P., Cittadella R., Andreoli V., La Russa A., Annesi F., Spadafora P., Romeo N., Nicoletti G., Messina D., Gambardella A., and Quattrone A. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch. Neurol. 61 (2004) 341-344